Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-30
2006-05-30
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S276700
Reexamination Certificate
active
07053108
ABSTRACT:
A compound of formula (I):wherein:R1and R2together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3represents hydrogen,orR1represents hydrogen, and R2and R3together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicaments.
REFERENCES:
patent: 6221884 (2001-04-01), Flaugh
Wijngaarden et al. Recl. Trav. Chim. Pays-Bas, 1993, 112:126-130.
Barnes et al. Neuropharmacology, 1999, 38: 1083-1085 and 1107-1110.
Berendsen, et al.,Psychopharmacology, 1990, 101, 57-61.
Millan, et al.,European Journal of Pharmacology, 1997, 325, 9-12.
O'Neill, et al.,Pharmacology, Biochemistry, and Behavior, 1999, 63, 237-243.
Reavill, et al.,British Journal of Psychopharmacology, 1999, 126, 572-574.
Herrick-Davis, et al.,Journal of Pharmacology and Experimental Therapeutics, 2000, 295, 226-232.
Wood, et al.,Drug Development Research, 2001, 54, 88-94.
Paiva, et al.,Psychopharmacology, 1988, 96, 395-399.
Dugovic,Journal Sleep Research, 1992, 1, 1163-1168.
Landolt, et al.,Neuropsychopharmacology, 1999, 21, 455-466.
Sharpley, et al.,Biological Psychiatry, 2000, 47, 468-470.
Watson, et al.,Pharmacology, Biochemistry, and Behavior, 1991, 39, 605-612.
Foreman, et al.,Life Sciences, 1989, 45, 1263-1270.
Klint, et al.,Psychopharmacology, 1995, 119, 291-294.
Hirschfeld,Journal of Clinical Psychiatry, 60 Suppl. 17:32-35, 1999.
Popova, et al.,Neuroendocrinology, 2002, 76, 28-34.
Amesergide, LY-237733;Pharmaproject, Phase II Clinical Trial, 2005.
Koskinen, et al.,Pharmacology, Biochemistry and Behavior, 2000, 66, 729-738.
White, et al.,Pharmacology, Biochemistry and Behaviour, 1991, 39, 729-736.
Millan, et al.,Journal of Pharmacology and Experimental Therapeutics, 2001, 298, 581-591.
Mundo, et al.,International Clinical Psychopharmacology, 2000, 15, 69-76.
Millan, et al.,Prog. Neurobiol., 1999, 57, 1-164.
Millan, et al.,Prog. Neurobiol., 2002, 66, 355-474.
Kalkman, et al.,Int. J. Clin. Pharmacol. Res., 1997, 17, 75-77.
Kalkman, et al.,Naunyn Schmiedebergs. Arch. Pharmacol., 1994, 350, 225-229.
Kalkman, et al.,Life Sci., 1994, 54, 641-644.
Ro-60-0759,Pharmaproject, Preclinical Trial, 2005.
SB-243213,Pharmaproject, Phase I Clinical Trial, 2005.
LY-053857,Pharmaproject, Phase II Clinical Trial (2005).
Kant,Pharmacol. Biochem. Behav., 1998, 59, 729-735.
Meneses, et al.,Behav. Brain Res., 1997, 87, 105-110.
Kant,Pharmacol. Biochem. Behav., 1996, 53, 385-390.
Di Giovanni, et al.,Indian J. Exp. Biol., 2002, 40, 1344-1352.
De Deurwaerdere, et al.,Trends Pharmacol. Sci., 2001, 22, 502-504.
Millan, et al.,Neuropharmacology, 1998, 37, 953-955.
Fox, et al.,Drug News and Perspectives, 1999, 12:477-483.
Fox, et al.,Movement Disorders, 2000, 15:1064-1069.
SM-3163,Pharmaproject, Phase II Clinical Trial (2005).
Gobert Alain
Lavielle Gilbert
Millan Mark
Muller Olivier
Hueschen and Sage
Les Laboratoires Servier
Morris Patricia L.
LandOfFree
Indoline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indoline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indoline compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3598141